Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use

Diabetologia

Volumn 62, Issue 6, 2019, Pages 939-947

  Potier, Louis ^a,b,c   Roussel, Ronan ^a,b,c   Velho, Gilberto ^c   Saulnier, Pierre Jean ^d,e,f   Bumbu, Anisoara ^a   Matar, Odette ^a   Schneider, Fabrice ^d,e,f   Ragot, Stéphanie ^d,e,f   Marre, Michel ^a,b,c,g   Mohammedi, Kamel ^h,i,j   Hadjadj, Samy ^k  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e UNIVERSITÉ DE POITIERS   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j INSERM U657   (France)

^k NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Diuretics; Lower limb amputation; Lower limb revascularisation; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; CANAGLIFLOZIN;

AGED; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEG AMPUTATION; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; AMPUTATION; LOWER LIMB; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES;

AGED; AMPUTATION; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LOWER EXTREMITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85062448543     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-019-4835-z     Document Type: Article

References (28)

1. van Houtum WH, Lavery LA, Harkless LB (1996) The impact of diabetes-related lower-extremity amputations in The Netherlands. J Diabetes Complications 10(6):325–330. 10.1016/1056-8727(95)00088-7
2. Davis WA, Norman PE, Bruce DG, Davis TM (2006) Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 49(11):2634–2641. 10.1007/s00125-006-0431-0
3. Martinez-De Jesus FR (2010) A checklist system to score healing progress of diabetic foot ulcers. Int J Low Extrem Wounds 9(2):74–83. 10.1177/1534734610371594
4. Sharefkin JB, Silen W (1974) Diuretic agents: inciting factor in nonocclusive mesenteric infarction? JAMA 229(11):1451–1453. 10.1001/jama.1974.03230490039020
5. O’Rourke DA, Hede JE (1978) Reversible leg ischaemia due to diuretics. Br Med J 1(6120):1114. 10.1136/bmj.1.6120.1114
6. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657. 10.1056/NEJMoa1611925
7. Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG (2004) Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. Pharmacoepidemiol Drug Saf 13(3):139–146. 10.1002/pds.932
8. Gary T, Belaj K, Hafner F et al (2015) Graz critical limb ischemia score: a risk score for critical limb ischemia in peripheral arterial occlusive disease. Medicine (Baltimore) 94(27):e1054. 10.1097/MD.0000000000001054
9. Hadjadj S, Fumeron F, Roussel R et al (2008) Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care 31(9):1847–1852. 10.2337/dc07-2079
10. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612. 10.7326/0003-4819-150-9-200905050-00006
11. Fine JP (2001) Regression modeling of competing crude failure probabilities. Biostatistics 2(1):85–97. 10.1093/biostatistics/2.1.85
12. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS (2005) Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 25(1):65–70. 10.1161/01.ATV.0000149377.90852.d8
13. Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399–424. 10.1080/00273171.2011.568786
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981–2997. 10.1001/jama.288.23.2981
15. Brown MJ, Palmer CR, Castaigne A et al (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356(9227):366–372. 10.1016/S0140-6736(00)02527-7
16. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG (2007) Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 28(3):354–362. 10.1093/eurheartj/ehl441
17. Leaf A (1973) Cell swelling. A factor in ischemic tissue injury. Circulation 48(3):455–458. 10.1161/01.CIR.48.3.455
18. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N (2018) Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 137(14):1450–1459. 10.1161/CIRCULATIONAHA.117.031227
19. Fadini GP, Avogaro A (2017) SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 5(9):680–681. 10.1016/S2213-8587(17)30257-7
20. Khouri C, Cracowski JL, Roustit M (2018) SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab 20(6):1531–1534.10.1111/dom.13255
21. Adimadhyam S, Lee TA, Calip GS, Smith Marsh DE, Layden BT, Schumock GT (2018) Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study. Diabetes Obes Metab 20(12):2792–2799. 10.1111/dom.13459
22. Yuan Z, DeFalco FJ, Ryan PB et al (2018) Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab 20(3):582–589. 10.1111/dom.13115
23. Radholm K, Wu JH, Wong MG et al (2018) Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review. Diabetes Res Clin Pract 140:118–128. 10.1016/j.diabres.2018.03.027
24. Dawwas GK, Smith SM, Park H (2019) Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Obes Metab 21(1):28–36. 10.1111/dom.13477
25. Chang HY, Singh S, Mansour O, Baksh S, Alexander GC (2018) Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med 178(9):1190–1198. 10.1001/jamainternmed.2018.3034
26. Ryan PB, Buse JB, Schuemie MJ et al (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20(11):2585–2597. 10.1111/dom.13424
27. Ueda P, Svanstrom H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365
28. Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41(1):e4–e5. 10.2337/dc17-1551